Tirzepatide, initially approved by the FDA for type 2 diabetes management, has also gained approval for aesthetic purposes, particularly in weight loss. This highly effective medication targets key hormones involved in regulating appetite, leading to significant reductions in body weight. A pivotal study highlighted its efficacy: participants undergoing intensive lifestyle changes followed by weekly Tirzepatide injections lost an average of 27% of their total body weight, about 64 pounds, over 72 weeks. This study, “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial,” published in JAMA in 2024, demonstrates Tirzepatide’s potential as an effective weight loss treatment. The combination of pharmacological intervention with lifestyle modifications proved crucial in achieving these results. Tirzepatide’s approval for aesthetic use underlines its role in addressing obesity, a condition with significant health and aesthetic implications.
Semaglutide is given through a subcutaneous injection once per week.
Reference:
First Dose Evaluation
MEDICAL ASSESSMENT AND DOSAGE TRIAGE
$225
1-Month Package
Most popular
FIRST DOSE EVALUATION FEE APPLIED TOWARD PACKAGE ENROLLMENT
$800
2-Month Package
Preferred pricing
FIRST DOSE EVALUATION FEE APPLIED TOWARD PACKAGE ENROLLMENT
$1200
3-Month Package
Best value
FIRST DOSE EVALUATION FEE APPLIED TOWARD PACKAGE ENROLLMENT
$1500
All monthly programs include clinically appropriate dosage escalation, provider follow-ups, standard titration protocols, and ongoing patient support.
